SAN DIEGO & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla’s investigational CAB CTLA-4 antibody.
2020 © Copyright - TPMG
SAN DIEGO & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla’s investigational CAB CTLA-4 antibody.